Lagoda Investment Management LP has recently announced that it has increased stake in Stereotaxis Inc. (AMEX:STXS) by 34.66%. After grabbing 2.19 million shares, the institutional investor is now in possession of 0.56 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 2.93% having worth around $4.54 million. Moreover, Millennium Management LLC increased its share by 0.31 million to have a control over 1.2 million shares. And Parian Global Management LP raised its holdings to 96142.0 shares by acquiring 0.82 million shares or 1.10% of the stake.
Stereotaxis Inc. (STXS) concluded trading on 01/19/23 at a closing price of $2.19, with 0.19 million shares of worth about $0.41 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 1.39% during that period and on Thursday the price saw a loss of about -5.60%. Currently the company’s common shares owned by public are about 76.10M shares, out of which, 63.24M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 6 analysts are covering the STXS stock and their offered price forecasts bring an average price target of $5.83. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $7.00 and could fall to a lowest price of $5.00. The stock’s current price level is 66.92% above of average price target set by the analysts, while a rise to estimated low would result in gain of 56.2% for the stock. However, touching the estimated high of $7.00 would mean a gain of 68.71% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 16 times over the past 12 months. They bought 333,530 shares in 16 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Total Stock Market Index, Rhenman & Partners Fund – Healthc, and Vanguard Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Stereotaxis Inc. Vanguard Total Stock Market Index is currently holding 1.39 million shares of worth totaling $2.87 million. The company recently came buying 665.0 shares which brought its stake up to 1.86% of the company’s outstanding shares. Rhenman & Partners Fund – Healthc bought 0.12 million shares, after which its hold over company’s outstanding shares expand to 1.07%, leaving 0.8 million shares with the mutual fund that have a worth of about $1.66 million. Vanguard Extended Market Index Fu, after buying 0.64 million shares, have now control over 0.85% of the stake in the company. It holds 0.0 shares of worth $1.32 million.
Stereotaxis Inc. (AMEX: STXS) started trading at $2.30, below -$0.02 from concluding price of the previous day. However, the stock later moved at a day high price of 2.4000, or with a loss of -5.60%. Stock saw a price change of -7.20% in past 5 days and over the past one month there was a price change of 9.50%. Year-to-date (YTD), STXS shares are showing a performance of 5.80% which decreased to -59.14% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.55 but also hit the highest price of $5.64 during that period. The average intraday trading volume for Stereotaxis Inc. shares is 189.99K. The stock is currently trading 2.24% above its 20-day simple moving average (SMA20), while that difference is up 3.70% for SMA50 and it goes to 1.14% higher than SMA200.
Lagoda Investment Management LP acquired 2.19 million shares of Stereotaxis Inc. having value of about $4.54 million. Data submitted at the U.S SEC by Lagoda Investment Management LP revealed that the firm now holds 0.56 million shares in the company valued at close to $1237131.0, or have control over 34.66% stake in the company. Stereotaxis Inc. (AMEX: STXS) currently have 76.10M outstanding shares and institutions hold larger chunk of about 49.00% of that. Holding of mutual funds in the company is about 42.49% while other institutional holders and individual stake holders have control over 6.74% and 39.13% of the stake respectively.
The stock has a current market capitalization of $163.90M and its 3Y-monthly beta is at 1.73. It has posted earnings per share of -$0.25 in the same period. It has Quick Ratio of 2.40 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for STXS, volatility over the week remained 9.69% while standing at 7.29% over the month.
Analysts are in expectations that Stereotaxis Inc. (STXS) stock would likely to be making an EPS of -$0.06 in the current quarter, while forecast for next quarter EPS is -$0.07 and it is -$0.19 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.07 which is -$0.05 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.07 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -44.90% while it is estimated to increase by 25.90% in next year.
Analysts at 6 brokerage firms have issued recommendations for the Stereotaxis Inc. (STXS)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.10. Out of those 6 Wall Street analysts, 6 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Aegis Capital on July 12, 2022 offering a Buy rating for the stock and assigned a target price of $6 to it. Coverage by B. Riley Securities stated Stereotaxis Inc. (STXS) stock as a Buy in their note to investors on June 23, 2022, suggesting a price target of $6 for the stock. On January 05, 2022, Loop Capital Initiated their recommendations, while on January 05, 2022, Craig Hallum Initiated their ratings for the stock with a price target of $11. Stock get an Overweight rating from Piper Sandler on May 26, 2021.